This HTML5 document contains 64 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01054/identifier/wikipedia/
n22http://linked.opendata.cz/resource/mesh/concept/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01054/identifier/pharmgkb/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01054/identifier/kegg-compound/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01054/identifier/bindingdb/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01054/identifier/pubchem-compound/
n23http://bio2rdf.org/drugbank:
n14http://linked.opendata.cz/resource/drugbank/drug/DB01054/identifier/pubchem-substance/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01054/identifier/kegg-drug/
admshttp://www.w3.org/ns/adms#
n19http://linked.opendata.cz/resource/drugbank/drug/DB01054/identifier/drugbank/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01054/identifier/iuphar/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01054/identifier/guide-to-pharmacology/
n4http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/drugbank/
n21http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n6http://linked.opendata.cz/resource/drugbank/property/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01054/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01054
rdf:type
n5:Drug
n5:description
A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive. [PubChem]
n5:group
approved
n5:indication
For the treatment of mild to moderate hypertension
owl:sameAs
n4:DB01054 n23:DB01054
dcterms:title
Nitrendipine
adms:identifier
n8:50012016 n11:4351 n12:PA146096020 n13:Nitrendipine n14:46508817 n15:D00629 n16:4507 n17:2334 n18:C07713 n19:DB01054 n20:2334
n5:mechanismOfAction
By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Nitrendipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
n5:synonym
1,4-dihydro-2,6-Dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid ethyl methyl ester Bayotensin Nidrel Nitrendipino Nitrendipinum BAY e 5009 Deiten Baypress Bylotensin
n5:proteinBinding
> 99%
n5:synthesisReference
Wolfgang Schmidt, Bernhard Streuff, Manfred Winter, "Preparation of solid medicament formulation containing nitrendipine." U.S. Patent US4724141, issued April, 1980.
n21:hasConcept
n22:M0014876
n5:IUPAC-Name
n6:271B5BA0-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B5BA6-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B5BA5-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B5BA2-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B5BA3-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B5BA4-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B5BB5-363D-11E5-9242-09173F13E4C5 n6:271B5B9E-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B5B9F-363D-11E5-9242-09173F13E4C5 n6:271B5BB7-363D-11E5-9242-09173F13E4C5 n6:271B5B9C-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B5B9D-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n10:C08CA08
n5:H-Bond-Acceptor-Count
n6:271B5BAC-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B5BAD-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B5BA7-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B5BA8-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B5BAA-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B5BA9-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B5BAB-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Humans and other mammals
n5:caco2-Permeability
n6:271B5BB8-363D-11E5-9242-09173F13E4C5
n5:casRegistryNumber
39562-70-4
n5:category
n5:Bioavailability
n6:271B5BB1-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B5BB3-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B5BB4-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B5BB6-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B5BB0-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B5BAF-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B5BB2-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B5BA1-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B5BAE-363D-11E5-9242-09173F13E4C5